Home > Drugs A – Z > Emtricitabine/Tenofovir (By mouth)

Emtricitabine/Tenofovir (By mouth)

Treats HIV infection. Also used to reduce the risk of HIV infection. This medicine does not cure HIV.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Emtricitabine and tenofovir disoproxil fumarate combination is used together with other medicines to treat human immunodeficiency virus (HIV) infection. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). This medicine is also used as part of a complete prevention strategy (Pre-Exposure prophylaxis) to reduce the risk of getting HIV infection in adults who are at high risk. … Read more
Brand names include
Truvada
Drug classes About this
Antiretroviral Agent
Combinations including this drug

What works? Research summarized

Evidence reviews

Addendum to Commission A12-02 (Rilpivirine / Emtricitabine / Tenofovir) [Internet]

The aim of this report was to assess the added benefit of the fixed-dose combination rilpivirine / emtricitabine / tenofovir compared to the appropriate comparator therapy (ACT) (efavirenz in combination with emtricitabine / tenofovir) in the approved therapeutic indication (human immunodeficiency virus type 1 [HIV-1] infection in antiretroviral-naïve adult patients with a viral load of ≤ 100,000 HIV-1 RNA copies/mL).

Rilpivirine / emtricitabine / tenofovir -- Benefit Assessment According to §35a Social Code Book V [Internet]

The aim of this report was to assess the added benefit of the fixed-dose combination rilpivirine / emtricitabine / tenofovir disoproxil (RIL / EMTRI / TENO) compared to the appropriate comparator therapy (ACT) (efavirenz in combination with emtricitabine / tenofovir) in the approved therapeutic indication (human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/mL).

Rilpivirine / Emtricitabine / Tenofovir (New Therapeutic Indication) -- Benefit Assessment According to §35a Social Code Book V [Internet]

The aim of the present report was to assess the added benefit of the drug combination rilpivirine / emtricitabine / tenofovir disoproxil (hereinafter referred to as RPV / FTC / TDF) for the new therapeutic indication of RPV / FTC / TDF approved in November 2013 in comparison with the appropriate comparator therapy (ACT). The assessment referred to adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load ≤ 100 000 HIV-1 ribonucleic acid (RNA) copies/mL who have received previous antiretroviral treatment.

See all (28)

Summaries for consumers

Emtricitabine / tenofovir alafenamide (Descovy) for HIV: Follow-up treatment in adults: Emtricitabine / tenofovir alafenamide (Descovy) for HIV

In 2016, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of emtricitabine / tenofovir alafenamide compared to the standard treatments for adults with HIV who have had treatment before. Individualized therapy is an option for these patients. This looks at which treatments were tried before and why they were discontinued. For instance, the previous treatment may have been ineffective or caused very severe side effects.The manufacturer provided provisional results from two studies involving patients who had already taken standard HIV drugs.In one study, 306 people who had been taking standard HIV drugs were instead given the fixed-dose combination emtricitabine / tenofovir alafenamide. The remaining 153 people continued taking the standard combination emtricitabine / tenofovir disoproxil. Both groups were also given elvitegravir and cobicistat.In the other study, 334 people stopped taking the standard drugs and instead took emtricitabine / tenofovir alafenamide, while the comparison group (334 people) continued treatment with emtricitabine / tenofovir disoproxil. These two groups received additional drugs as well.

Emtricitabine / rilpivirine / tenofovir alafenamide (Odefsey) for HIV: Overview

The fixed combination of emtricitabine / rilpivirine / tenofovir alafenamide (trade name: Odefsey) has been approved in Germany since June 2016 for the treatment of type 1 HIV in adults and children aged 12 and over.

Rilpivirine (Edurant, Eviplera) for the treatment of HIV: Initial treatment in adults: Rilpivirine (Eviplera) in a fixed-dose combination with emtricitabine / tenofovir

Patients starting their first HIV treatment are often given efavirenz in combination with two other drugs. Emtricitabine and tenofovir are one of several pairs of drugs that can be used in this way.In early 2012, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of rilpivirine taken in a fixed-dose combination with emtricitabine / tenofovir (trade name: Eviplera), compared with the fixed-dose combination efavirenz plus emtricitabine / tenofovir. Three studies were available to IQWiG.

See all (12)

PubMed Health Blog...

read all...